Vibativ Related Published Studies
Well-designed clinical trials related to Vibativ (Telavancin)
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. [2011.01.01]
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive
pathogens. [2011]
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. [2010.12]
Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. [2010.02]
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. [2009.07]
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. [2009.06]
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. [2008.10]
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. [2008.06.01]
Well-designed clinical trials possibly related to Vibativ (Telavancin)
Meta-analysis of randomized controlled trials of vancomycin for the treatment of
patients with gram-positive infections: focus on the study design. [2012]
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis,
treatment and resistance. [2012]
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. [2009.12]
Other research related to Vibativ (Telavancin)
The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for
the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. [2014]
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. [2011.03]
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. [2011.02]
An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic. [2011.01]
Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults. [2010.12]
Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. [2010.12]
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. [2010.12]
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections. [2010.10]
In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. [2010.10]
Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. [2010.08]
Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. [2010.08]
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. [2010.05.07]
Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. [2010.04]
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. [2010.01]
Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. [2010.01]
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the
treatment of skin infections. [2010]
Telavancin: a novel lipoglycopeptide. [2009.12.15]
Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. [2009.12]
Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. [2009.06]
Telavancin: a novel lipoglycopeptide antibiotic. [2009.05]
The role of telavancin in the treatment of MRSA infections in hospital. [2009.04]
Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. [2009.04]
Telavancin: a new lipoglycopeptide for gram-positive infections. [2009.03]
Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. [2009.02]
Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. [2009]
Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. [2008.12]
Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. [2008.11]
A new lipoglycopeptide: telavancin. [2008.08]
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. [2008.07]
Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. [2008.07]
Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. [2008.04]
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). [2008.02]
Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. [2008.02]
Other possibly related research studies
Treatment of infections caused by antimicrobial-resistant gram-positive bacteria. [2010.09]
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. [2010.08.17]
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. [2010.07]
New antimicrobial agents for methicillin-resistant Staphylococcus aureus. [2009.12]
Future treatment options for Gram-positive infections--looking ahead. [2009.12]
[Update on antimicrobial chemotherapy] [2010.03]
Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. [2009.09]
Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. [2009.09]
Has the era of untreatable infections arrived? [2009.09]
Antimicrobial development in the era of emerging resistance. [2009.07]
New treatments for methicillin-resistant Staphylococcus aureus. [2009.10]
Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. [2009.03]
[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica] [2009.02]
New antibiotics for healthcare-associated pneumonia. [2009.02]
Vancomycin resistance: are there better glycopeptides coming? [2008.12]
[New antimicrobials against Gram-positive organisms] [2008]
Emergence and management of drug-resistant enterococcal infections. [2008.10]
Investigational antimicrobial drugs for bloodstream infections. [2008.08]
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in? [2008]
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. [2008.02]
Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. [2008.01]
Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. [2008.02]
Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. [2007.12]
Treatment of infections caused by resistant Staphylococcus aureus. [2007]
Current medical management of diabetic foot infections. [2010.11]
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. [2010.11]
Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. [2010.08]
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus
(MRSA) pneumonia: current and future options. [2010]
|